Kepler Capital Markets set a CHF 236 price objective on Roche (VTX:ROG) in a research note issued to investors on Tuesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. reissued a buy rating and set a target price on shares of Roche in a report on Thursday, November 2nd. Berenberg Bank set a CHF 260 target price on shares of Roche and gave the company a neutral rating in a report on Monday, November 20th. Societe Generale set a CHF 190 target price on shares of Roche and gave the company a sell rating in a report on Monday, January 15th. HSBC set a CHF 205 target price on shares of Roche and gave the company a sell rating in a report on Tuesday, November 21st. Finally, Jefferies Group set a CHF 290 target price on shares of Roche and gave the company a buy rating in a report on Thursday, November 16th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of CHF 256.55.
Shares of Roche (VTX:ROG) opened at CHF 223.90 on Tuesday. Roche has a 1-year low of CHF 214.30 and a 1-year high of CHF 273. The stock has a market cap of $194,790.00 and a price-to-earnings ratio of 22.30.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/kepler-capital-markets-analysts-give-roche-rog-a-chf-236-price-target.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.